Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
about
P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferationTargeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsCHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycleTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyTargeting the Mitotic Catastrophe Signaling Pathway in CancerTargeting the Checkpoint to Kill Cancer CellsDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responseStructure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold MorphingGli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitorsNovel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersRoles of Chk1 in cell biology and cancer therapyChk1 targeting reactivates PP2A tumor suppressor activity in cancer cellsDDRI-9: a novel DNA damage response inhibitor that blocks mitotic progressionThe causes and consequences of genetic heterogeneity in cancer evolutionReversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacyA phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell deathRe-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpointsDynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapyWild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cellsFunctional kinomics identifies candidate therapeutic targets in head and neck cancerATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1.Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targetsGenistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cellsMulticellular tumor spheroid models to explore cell cycle checkpoints in 3D.Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapyCombined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Triple-negative breast cancer: new perspectives for targeted therapies.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersTargeting lung cancer through inhibition of checkpoint kinases.Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesEnhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
P2860
Q24305925-D522C810-BD23-4787-A352-7CC82B5EB710Q24610287-1677B548-5158-4D38-84F5-26CDFA2674F5Q24622357-4335ED30-7436-4EE4-8F25-80FDAF875384Q26745686-F9B5497F-AFA4-4B5F-8090-C203B4466A88Q26778544-606FDB91-115E-4159-A938-2193D7D72C5FQ26795781-EF34FC2C-D376-45BD-986D-CD792AF74512Q26829155-6C1636E3-9059-45D1-90CB-52D8E9C97583Q26864870-ABBF9C10-5190-4E66-BB01-75531925F092Q27014080-F92573B1-0FC6-493B-B631-AF7B26A7C152Q27675773-479E6466-9608-470B-8BF7-9DB351A3C5E0Q28248615-19043228-FC3F-47EC-B940-508E118D5BC5Q28262425-3CA5F00E-7200-4DD1-ACF2-0BB5034C1676Q28271944-325F3110-D19C-4CD3-84A9-1C570386AF87Q28289548-CDB4FEFE-437A-400E-A672-8A4C5AA4935CQ28299365-51F6B4D1-4FF9-446B-9E14-D0C1747CD960Q28829581-C1627C25-458F-4704-945C-F24AE93D4FCDQ29615848-2CCFFE47-89BD-4B65-BC69-B3D9D6C30AA9Q30366115-3B56491C-EF5F-452A-9136-04745FBA829BQ30422919-AD21D719-FB79-47CE-9387-79F80452F42EQ30570001-AC6BE828-9A03-484D-9B5A-C5214AE21604Q30584974-01A84063-6A77-4A9B-935F-8327DD711309Q31090728-64AA149F-930F-42D4-9A2F-C6070DCFDEA3Q33739235-C1F8C373-D46C-4AC2-ADB0-1F335549BA09Q33778215-713917F9-A50D-45B9-A963-65164512DC03Q33815609-E05BCFBE-1EAA-4947-89FC-BEA52DA57F55Q34055936-782F3002-37E2-46CE-AD73-63BB6289C380Q34115685-E9D90760-FE51-4850-9B16-8A35AAC4EF96Q34248336-83C5B197-D013-43D1-9ADA-A93002762D5EQ34287982-24D000D2-47F0-4060-BFE0-C25A47296BDFQ34309214-0CEE7B6B-F845-47DB-B34B-D0D52BC27123Q34504946-411F0230-BE2F-4802-9B07-B0BE631F3042Q34564108-0DE945BD-A1CE-44ED-A80A-EA77ECF6B7A2Q34581413-9DC5C377-72E7-4604-8944-FE555DAB938DQ34654741-6458055B-8647-4A6E-B504-A415754F72B2Q34978486-8D73A2B1-A652-4289-97E1-DD79BB294ABCQ35001758-DD88CDF8-304C-4181-974A-5BE74FE94B9BQ35070685-A800D022-ACAB-4937-B690-B5F8B22B0764Q35128547-BCFD9D8F-338F-4BDC-8027-580121274129Q35212640-0F265617-C1C6-45DD-91C3-841CC2EF51F2Q35637224-CECE2640-A76F-4A75-A1F1-A9AFDED2E689
P2860
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@ast
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@en
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@nl
type
label
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@ast
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@en
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@nl
prefLabel
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@ast
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@en
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@nl
P3181
P1476
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
@en
P2093
Cynthia X Ma
Helen Piwnica-Worms
P3181
P356
10.1016/J.MOLMED.2010.10.009
P407
P577
2011-02-01T00:00:00Z